Navigation Links
"PATH B": A Comprehensive Support Programme in Europe for Patients Diagnosed With Chronic Hepatitis B Launched

PARIS, October 21, 2011 /PRNewswire/ --

  • Hepatitis B is one of the most common infectious diseases in the world, with 350  million people worldwide being chronically infected [1] - this compares with 33 million people living with HIV infection [2]- yet there remains a lack of reliable resources for hepatitis B patientsand caregivers
  • PATH B - "Patients and Professionals Acting Together for Hepatitis B" ( - is a new programme that provides information and tools to guide patients through their journey with chronic hepatitis B from diagnosis to long-term disease management

A pioneering educational resource, designed to improve the lives of people living with chronic hepatitis B, was launched today at an annual conference organised by Bristol-Myers Squibb in Hong Kong where 26 patient advocacy groups from 14 countries and regions gathered to discuss viral hepatitis.

The PATH B ("Patients and Professionals Acting Together for Hepatitis B") programme was developed by an international advisory board comprising people living with hepatitis B, as well as patient advocacy group representatives and leading hepatologists from across Europe. This programme is provided as an educational service by the World Hepatitis Alliance (WHA) and The European Liver Patients Association (ELPA). The programme was organised and funded by Bristol-Myers Squibb.

The European Association for the Study of the Liver (EASL) also welcomed "the scope of the information the Path B resource provides to patients."

Professor Mark Thursz, Secretary General of the European Association for the Study of the Liver commented: "This resource provides comprehensive and reliable information for patients diagnosed with hepatitis B.  I have no doubt that PATH B will help patients to be better informed, empowered and equipped to manage their treatment journey."

The core component of the PATH B programme is a patient-centric resource, PATH B - My journey with chronic hepatitis B.  This extensive interactive educational resource consists of a hepatitis B journey roadmap that guides patients through every step and aspect of hepatitis B and treatment options. The six stages of the roadmap cover key aspects of a patient's journey with essential information from diagnosis to long-term disease management.

"There is a large information gap for chronic hepatitis B patients between their initial diagnoses and the long-term management of their disease," said PATH B advisory board member, Achim Kautz, ELPA Board Member. "For the first time, this toolkit seeks to fill that unmet need for complete and reliable information that patients can depend on through every step of their disease."

An innovation contained within the PATH B resource is the online diary where patients can record notes, test results, write in medical appointments as well as any disease or treatment related problems they may experience. The resource contains also a 'View Your Progress' tool, which, for the first time, allows patients to plot their test results over time and to chart the progress of their treatment. The aim of this tool is to help patients understand their treatment, therefore aiding adherence.

Charles Gore, President of the World Hepatitis Alliance, praised the resource: "PATH B is the first of its kind in terms of the range of patient materials available in such a portable interactive format. It really does provide practical help for patients."

The PATH B resource was also designed to facilitate better patient-physician dialogue, and to provide trustworthy information.

"As a clinician, I have seen that patients who are more knowledgeable about their disease feel empowered and in control and tend to have better outcomes," said PATH B advisory board member, Dr. Mark Wilkinson of Guy's and St Thomas' Hospital, London, UK.

Although this resource was developed primarily for patients it can also be a helpful tool for physicians to enhance dialogue with patients on disease progression, treatment and the importance of adherence and persistency.

The advisory board members included representatives from the following:

To view and download the English version of the PATH B education resource please visit More language versions, including German, French, Spanish, Italian, traditional Chinese, Turkish, Portuguese and Russian will be launched early next year.


1. World Health Organization. Hepatitis B Fact Sheet. Available at  Accessed on 1 July 2011

2. Global Report. Chapter introduction. Available at  Accessed on 11 October 2011

Media Contacts:

Raquel Jose, International Relations Director, WHA (World Hepatitis Alliance)
Tel: +44-7920-202-120 Email:

Achim Kautz, Board member ELPA (European Liver Patients Association)
Tel: +49-1-784429570 Email:

Annie Simond, Director, Global Public Affairs, Virology, Bristol-Myers Squibb
Tel: +33-6-08-95-67-62 Email:

SOURCE Bristol-Myers Squibb
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ReportsnReports - Daptomycin - Comprehensive Patent Search
2. MEMS Materials and Processes Handbook -- a comprehensive, practical resource
3. ACO Proposed Rule Simplified: MedeAnalytics Releases Comprehensive White Paper
4. Georgetown Lombardi Comprehensive Cancer Center Taps Ariadne for G-DOC Pathway Data and Tools
5. Reportlinker Adds Amphotericin B - Comprehensive patent search
6. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
7. Terrorist de-radicalization shows promise, comprehensive study finds
8. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
9. Three Nephrology TreatmentTrends Publications from BioTrends Provide a Comprehensive View of Bone and Mineral Metabolism Practice Patterns Around the Globe
10. Colorado Center for Reproductive Medicine Improves Pregnancy and Implantation Rates Using Comprehensive Chromosomal Screening of IVF Embryos
11. Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... report "Electronic Sensors Market for Consumer Industry by Type ... Others), Application (Communication & IT, Entertainment, Home ... Global Forecast to 2022", published by MarketsandMarkets, ... expected to reach USD 26.76 Billion by ...
Breaking Biology News(10 mins):